Modulating multidrug resistance: Can we target this therapy?

Clinical Cancer Research

Volumn 8, Issue 3, 2002, Pages 633-635

  Murren, John R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BIRICODAR; CYCLOSPORIN; CYCLOSPORIN DERIVATIVE; EPIPODOPHYLLOTOXIN DERIVATIVE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; QUINIDINE; TAMOXIFEN; TAXANE DERIVATIVE; VALSPODAR; VERAPAMIL; VINCA ALKALOID; ZOSUQUIDAR;

CANCER RESISTANCE; CYTOTOXICITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; EDITORIAL; GENE TARGETING; HUMAN; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SENSITIZATION;

DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN;

EID: 0036301347     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (25)

1. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: Cross-resistance, radioautographic, and cytogenetic studies
2. Classical and novel forms of multidrug resistance and the physiological functions of p-glycoprotein in mammals
3. The human ATP-binding cassette (ABC) transporter superfamily
4. Expression of the multidrug resistance gene product (p-glycoprotein) in human normal and tumor tissues
5. The multidrug resistance (mdr1) gene product functions as an ATP channel
6. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure
7. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
8. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA
9. Regulation of biliary drug efflux pump expression by hormones and xenobiotics
10. An altered pattern of cross-resistance in multidrug-resistant human cells results from the spontaneous mutations in the mdr1 (P-glycoprotein) gene
11. Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185->Val-185 substitution of P-glycoprotein
12. Pharmacology of drugs that alter multidrug resistance in cancer
13. Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil
14. Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates
15. Modulation of P-glyco-protein by protein kinase C α in a baculovirus expression system
16. Pharmacological characterization of LY335979: A potent cyclopropyldibenzosuberane modulator of P-glycoprotein
17. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP
18. Safety and efficacy of the multidrug resistance inhibitor incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel
19. Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional-significance
20. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833
21. Functional imaging of multidrug-resistant p-glycoprotein with an organotechnetium complex
22. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients
23. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer
24. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
25. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein